You just read:

Tocagen's Toca 5 Pivotal Phase 3 Clinical Trial in Patients with Recurrent Brain Cancer Continues Without Modification at Planned First Interim Analysis

News provided by

Tocagen Inc.

Aug 23, 2018, 08:00 ET